A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Master Protocol to Evaluate the Efficacy and Safety of Elecoglipron in Participants with Obesity or Overweight with or without Type 2 Diabetes Mellitus (Embold)
2026-09-10
عنوان الدراسة
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Master Protocol to Evaluate the Efficacy and Safety of Elecoglipron in Participants with Obesity or Overweight with or without Type 2 Diabetes Mellitus (Embold)
داعم الدراسة
Astrazeneca UK Ltd.
دواء الدراسة
Elecoglipron
رقم بروتوكول الدراسة
D7260C00015
حالة الدراسة
Ongoing
موقع الدراسة
King Fahad Specialist Hospital (Dammam)
مرحلة الدراسة
3
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.